European Union - English - EMA (European Medicines Agency)

ceva santé animale - genetically modified recombinant shiga-toxin-2e antigen - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - pigs - active immunisation of piglets from the age of four days, to reduce the mortality and clinical signs of oedema disease caused by shiga toxin 2e produced by escherichia coli (stec). onset of immunity: 21 days after vaccination. duration of immunity: 105 days after vaccination.,

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross diagnostics pty ltd - ct918 - pharmacogenetic ivds - for the simultaneous in vitro qualitative detection of gene mutations in dna to aid in the diagnosis of pharmacogenetic related toxicity in patients referred for drug therapy.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

africa biosystems tanzania ltd, tanzania - genetic analyzer -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

africa biosystems tanzania ltd, tanzania - genetic analyzer -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

africa biosystems tanzania ltd, tanzania - genetic analyzer -

Australia - English - Department of Health (Therapeutic Goods Administration)

myriad genetics pty ltd - ct929 - acquired genetic alteration ivds - an in vitro diagnostic kit for patients with estrogen-receptor-positive, her-2 negative primary breast cancer to determine the risk of distant recurrence and to estimate the adjuvant chemotherapy benefit.

Australia - English - Department of Health (Therapeutic Goods Administration)

genetic signatures ltd - ct355 - viral infectious disease ivds - the genetic signatures? easyscreentm enteric viral detection kit ( ref ev00

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross diagnostics pty ltd - ct918 - pharmacogenetic ivds - for the simultaneous in vitro qualitative detection of dpyd gene mutations associated with increased risk of severe or fatal toxicity in response to treatment with 5-fluorouracil (5-fu).

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct929 - acquired genetic alteration ivds - dna ivd probes intended to be used in genetic testing to provide information about acquired genetic alterations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct929 - acquired genetic alteration ivds - ivds that are intended to be used in genetic testing to provide information about acquired genetic alterations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information.